Multiple independent pre-clinical studies have demonstrated that DMT helps mitigate tissue damage and promote neurogenesis, as well as structural and functional neural plasticity. These are key factors involved in the brain’s ability to form and reorganize synaptic connections, which are needed for healing following a brain injury like an ischemic stroke. Join Algernon Pharmaceuticals CEO Christopher J. Moreau as he reviews the positive science and data driving the company’s pioneering Phase 1 clinical study of DMT for the treatment of stroke. Rick Strassman will be appearing through Zoom.